New Approaches in Prognostic Assessment and Personalized Treatment of Classical Hodgkin Lymphoma
Using Genetic Profiling, Liquid Biopsy, and Imaging Biomarkers
Led by Azienda USL Reggio Emilia - IRCCS · Updated on 2026-05-29
755
Participants Needed
12
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying Classical Hodgkins Lymphoma cHL, a rare cancer of the immune system mostly affecting young adults. Despite advances in treatment, many patients experience relapse or resistant disease. The study aims to better understand the genetic and biological complexity of cHL using molecular profiling and advanced imaging techniques, to identify new markers that predict disease progression and improve personalized treatments.
The study includes three groups patients who have completed treatment and entered follow-up, patients with confirmed relapse or disease progression, and a retrospective group of previously treated patients from medical archives. It combines genetic analysis, gene expression profiling, liquid biopsy of circulating DNA, and radiomic analysis of PET scans to capture tumor characteristics at diagnosis and during disease progression.
Participants will provide tissue and blood samples, and undergo PET scan evaluations. Researchers will analyze genetic mutations, compare findings from tissue and liquid biopsies, and correlate these data with patient outcomes. The study will track participants over several years to assess how genetic and imaging markers relate to disease control, aiming to improve risk assessment and treatment decisions in cHL.
CONDITIONS
Brief Title
Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
Research Team
A
Attilio Gennaro, Clinical Research Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
For Cohort A: histologically confirmed relapsed/refractory classical Hodgkin lymphoma during induction or follow-up
Available biopsy samples at diagnosis and progression for Cohort A
Available plasma sample at progression before salvage therapy for Cohort A
Available FDG-PET evaluation at study enrollment for Cohort A
Available clinical, laboratory, and imaging data at diagnosis and relapse for Cohort A
For Cohort B: classical Hodgkin lymphoma diagnosis
Completion of first-line standard treatment for Cohort B
Available plasma sample at end of treatment for Cohort B
Available biopsy at diagnosis for Cohort B
No further treatment planned for Cohort B
Willingness to undergo 6 months follow-up plasma collection and attend regular follow-up for Cohort B
For Cohort C: histologically confirmed classical Hodgkin lymphoma
Standard treatment as per guidelines for Cohort C
Available treatment, response, and follow-up data for Cohort C
Available biopsy at diagnosis for Cohort C
Available FDG-PET evaluation at study enrollment for Cohort C
You will not qualify if you...
Diagnosis of nodular lymphocyte predominant Hodgkin lymphoma
Active HIV infection
Active HBV infection
Active HCV infection
Presence of untreated cancer besides Hodgkin lymphoma
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - At enrollment
Participants provide biopsy samples and plasma samples, and undergo FDG-PET evaluation at enrollment to assess genetic and clinical status.
1 visit (in-person)
Long-term Monitoring
Duration - Up to 4 years
Participants are followed for up to 4 years with plasma collections and clinical assessments to monitor disease progression and correlate gene expression with clinical outcomes.
Regular follow-up visits over 4 years including plasma collections
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Pembrolizumab Treatment for Children and Teens with Advanced Melanoma, Solid Tumors, or Lymphomas
Study of Brentuximab Vedotin-Based Treatment for New Childhood and Young Adult Classical Hodgkin Lymphoma in China Using PETCT
New Approaches in Prognostic Assessment and Personalized Treatment of Classical Hodgkin Lymphoma
Using Genetic Profiling, Liquid Biopsy, and Imaging Biomarkers
Using ctDNA to Monitor Treatment and Predict Outcomes in Children and Young Adults with Classical Hodgkin Lymphoma
Evaluation of a Healthy Lifestyle Survivorship Care Plan to Improve Quality of Life in Long-Term Lymphoma Survivors A Randomized Behavioral Clinical Trial by Fondazione Italiana Linfomi
Phase 2 Study of Pembrolizumab with Chemotherapy for First-Relapsed or Refractory Classical Hodgkin Lymphoma in Adults Aged 18 to 65
Personalized Immunotherapy Treatment for Early-Stage Unfavorable Classical Hodgkin Lymphoma
Phase II Study Using Tislelizumab With or Without Chemotherapy
Phase II Study of Sintilimab Plus AVD Chemotherapy for Children and Teens with Low to Moderate Risk Classical Hodgkin Lymphoma
Evaluating Safety and Effectiveness of Pembrolizumab Combined With Bendamustine for Adults With Relapsed or Refractory Classical Hodgkin Lymphoma
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Francesco Merli, Stefano Luminari, Paolo G Gobbi...
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
Marc P E André, Théodore Girinsky, Massimo Federico...